T1	Participants 52 76	type 2 diabetic patients
T2	Participants 243 349	type 2 diabetes receiving exogenous insulin due to secondary failure of maximum dose sulphonylurea therapy
T3	Participants 361 375	single-centre,
T4	Participants 444 665	48 type 2 diabetic patients with late-term failure following at least 3 years of sulphonylurea therapy requiring additional insulin therapy to determine the impact of acarbose on glycaemic control and insulin requirements
T5	Participants 1920 1965	glycaemic control in type 2 diabetic patients
